Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're talking to a guy that's invested here a very long time. Even as long investors go, he's a senior citizen who knows this management far better than you realize. Here's the drug he's talking about. I'd suggest reading his posts more carefully. He's a gem of information. Ask him anything you want to know. He'll be straight up with you because he's got nothing to hide. Cut him some slack, he's definitely the most knowledgeable long here. I'd take him more seriously if I were you. Good luck.
~~~~~~~~~~~~~~~~~~~~~~~~
Crofelemer is a medication derived from the latex of the South American tree Croton lechleri. It is used to treat diarrhea, particularly in people with HIV/AIDS who are taking antiretroviral therapy. Crofelemer works by blocking certain chloride channels in the intestines, which helps to reduce the secretion of excess fluid and electrolytes, thereby improving stool consistency and reducing the frequency of bowel movements.
In clinical trials, crofelemer has shown effectiveness in reducing the duration and severity of diarrhea in people with HIV/AIDS who are on antiretroviral therapy. It has also been studied for its potential use in treating diarrhea associated with other conditions, such as chemotherapy-induced diarrhea and traveler's diarrhea.
Overall, crofelemer has been found to be a safe and effective treatment for diarrhea in certain patient populations. However, like any medication, it may not be suitable for everyone, and potential side effects should be discussed with a healthcare provider before starting treatment.
I asked him to be more engaging & informative.
Only reasonable, we were literally thrown under the bus first time around. He should be more polished now he's had the chance to work with more prospective companies. Also asked him for an investor Q& A web session. Anything's an improvement. I get this is a new company, he's getting his bearings & all. But he can make a better effort keeping investors in the loop that's for darn sure.
The perfect destination but a ways off
IMH*O
Now bare with me this will be controversial.
I honestly think Sonendo has plateaued technologically speaking. The reason I say that is because I don't think they'll be anything like this for years in any other company owing to the patent protections. What they will do is spread out sales to Europe, Australia, India Etc.
That said I've noticed Bjarne really likes his Tech! So I can't count him out. At some point he will be exporting the machines overseas as North American Sales flag a little. All in all, I see one heck of a bright future for Gentle Wave technology. A disruptive, game-changing transformative, paradigm shift!
We won't know timing till it happens
Anything other than that could spell disaster legally. Probably why the Nerve Center has developed a mysterious sore throat. But yes I hunch you are spot on! I had him down for Mid May or barring that Mid October.
Truth is no one is allowed to know or the uplisting is off.
Finally we're seeing a repetitive pattern here.
They did the same maneuver some months ago now. Chen, Watts and Bergheim this time, strikingly familiar names. The directors sluff off (dispose) of a few thousand seemingly inconsequential shares. Simultaneously Bjarne Bergheim loads the boat AGAIN
These shares being disposed of are definitely NOT INCONSEQUENTIAL but they sure are very interesting. New employee incentive shares perhaps... 🤔
OK fair enough I stand corrected
Uplisting near term is now Probable. You can't argue with that statement. Looks like he's doubling down. Doesn't get more bullish than that. Great find, strange I checked filings Friday and over the weekend as I recall.
Anyhow when management is loading up frankly I can't think of a more powerful indicator. Something's cooking...
Well well WELL, of course the parallel universe
https://x.com/xespninc?t=8DMWLvDAo_81EzVnV488lw&s=09
He's alive...
SONX enables progressive dentistry.
There are going to be revenue streams with Gentle Wave, that simply were not attainable before. SONX enables these lucrative revenue streams to the practitioner. Speed and vastly better anti-infection results are it's key selling features.
Think about it, if GentleWave only offered less trips to the doctor that's a good thing. But GentleWave also preserves your teeth much longer. I'd like to avoid dentures if I can. So Dentists and Endodontists that don't buy GentleWave will be making significantly less income per year.
If I had spent a million dollars to become a dentist, my dentist did BTW (never mind any Endodontists LORD). Geez I think I'd be pretty motivated to buy GentleWave as being a very significantly better Dentist's Office means significantly more revenue.
Are we talking the same language here? 👉💰💰
That's why difficult to contain my enthusiasm.
Below the gum line should be routinely cleaned every 6 months. Gum disease can be very hard on your heart and other organs. Where I live that's $325 bucks a cleaning.
I'm not clear if below gumline cleanings are done by CleanFlow®️ or GentleWave or both? If SONX can get recessive tartar done faster yet more efficiently. Then Gentle Wave is definitely the dental ATM machine... 💰💰
Yes Scottie for "Root Canals" correct✔️
Only thing is it needs FDA approval for all the other procedures or am I missing something. Which puts us back into speculation mode. What is Sonendo's most often used procedure. That is highly likely to be most revenue generating. The company gives a vague clue.
In that CleanFlow®️ is capable of sterilizing tooth decay from outside the tooth enamel. Insanely great but which procedure will that be? They have not given out that info. The only sensible reason is that it's still in lab testing. But the next most common procedure for CleanFlow®️ (an educated guess) will be the most revenue generating procedure to my way of thinking.
If I'm correct to generate enough revenue for financial qualifications to NYSE. I'm thinking that procedure has to be Cavities. Would you agree with me on that? We're like a fish out of water for company info but Cavities would be my best hunch based on what we are given... 🤔
6. Investment in AI startups will remain hot.
Investors poured money into AI startups last year, bucking a broader slowdown in the tech industry. Global venture-capital investment in GenAI startups totaled $23.2 billion from January through mid-October 2023, up about 250% from 2022’s full-year total, according to PitchBook.
The gold rush into AI startups is poised to continue this year. The reason boils down to the fact that investors will invest in innovation, and AI is set to become an even stronger and more versatile tool.
https://www.jdsupra.com/legalnews/what-s-next-for-ai-six-areas-to-watch-1719880/
He might be extremely busy & equally honest
Fact is he seriously lacks transparency. The average daily volume of 7, 065 shares bares witness to the fact outsiders are skeptical.
AI... if you're not using it your business is going to suffer. I remain optimistic but the Nerve Center needs to be more open with it's investors. If not, they are understandably hesitant if not downright nervous. This filing should put more eyes on the prize.
The average stick factor for web pages is a whopping 8 seconds. I hope he's considering an online prospectus or something that explains the company better, holding investor's attention. That would help his reputation on the pinks no end. Even an Investor's Zoom Q&A if easier because he's likely pretty busy...
SONX incommunicado on emails or calls...
Has anyone else heard from Sonendo lately?
I'm wondering if we are headed into a company 28 day Quiet Period.
Possible? Yyyup
Plausible? Are you kidding me of course absolutely!
Probable? If we are going on the presumption of not before CleanFlow®️Procedure Tool is ready for 10+ different procedures, and those are ready this soon OOOPHH! That's seems a stretch but then they really have been secretive on CleanFlow®️ for God knows how long?
I'm bumping the uplisting Quiet Period theory back down to Plausible. Sorry guys I just can't see them being that far advanced yet. Tad too soon in my books, some of these are extremely advanced procedures. Delighted if proven wrong, but my gut tells me not yet. Just trying to keep it real here.
Happy Saint Paddy's Day Scottie!
Interesting difference first glance is, retail needs to do well. Sonendo well aware they must keep employees at this critical a stage. If employee incentivization isnt working Sonendo is in a world of HR hurt at a vulnerable stage.
I get the strong impression company loyalty is high. Don't get me wrong, but seems the world is having a hard time finding employees right now. Covid boomer retirement void maybe not too sure the main reason.
Bullishness IMO clearly hinges on CleanFlow®️ Procedure Tool deployment and seamless approval. There's 10 different procedures I know of so lots of lab work and real word confirmation of efficacy. I could be wrong but that seems there modus operandi.
Make a big splash with CleanFlow®️ Procedure Tool that convinces NYSE they're here to stay in terms of listing requirements. I think they are, the revenue that instrument will generate the market simply can't process ATM. I can, a ship load of new patients all across North America and growing* at a speed we're not familiar with 🤭.
Word of mouth from Endodontists and Dentists will assure the public a hard to believe efficacy is the real deal. 1 million patients already will also attest to the Company’s reputation. Swelling Sonendo's revenue streams like never before in there history. 🍀
That's not dumb sir, great question how apropos.
Simply put there is no such SEC Board of Directors that interfere. The company has prerequisite qualifications set by the NYSE exchange they must meet in terms of financial performance, corporate governance standards, and minimum stock price thresholds. The decision if to uplist is normally made by the company's management and executive in observance of direction from it's legal and financial advisors.
SONX as confirmed in 4th quarter earnings is "in the process of uplisting to NYSE" . Sonendo's lawyers will advise SONX on any errors improvements etc. Primarily NYSE exchange will independently approve (or disapprove) of SONX's qualifications of NYSE's rules.
The SEC normally plays a role in regulating the Securities industry and ensuring compliance with Securities Law. In that vein the final conclusion of the process is SEC's approval that SONX may proceed with it's uplisting.
So your long answer is the company does the full brunt of the decision making through it's staff, management and lawyer's decisions, while the NYSE and SEC determine there approval in that order. Of course there will be obligatory back and forth collaboration at all levels. But at the end of the day... The Securities Exchange Commission always holds final* say.
Scotty sometimes we're zoomed in all day.
So it's healthy to step back from the macro at times and see the overall picture for a better sense of what's really going on.
Uplisting from the Over-the-Counter (OTC) market to a major exchange like the New York Stock Exchange (NYSE) can be a significant milestone for a company. Some indicators that a stock may be considering or preparing for an uplift to the NYSE include:
1. **Improved Financial Performance:** Consistent revenue growth, profitability, and strong financial metrics can make a company more attractive to major exchanges.
2. **Meeting Exchange Listing Requirements:** This includes meeting minimum share price requirements, having a certain number of shareholders, meeting financial standards, and complying with corporate governance standards.
3. **Increased Market Capitalization:** A higher market capitalization indicates a larger, more established company, which is often a prerequisite for listing on major exchanges.
4. **Enhanced Corporate Governance:** Adhering to higher standards of corporate governance, including transparency, accountability, and independent board members, is often a requirement for listing on major exchanges.
5. **Enhanced Reporting and Compliance:** Meeting or exceeding regulatory requirements, such as those set by the Securities and Exchange Commission (SEC), is essential for listing on major exchanges.
6. **Greater Investor Interest:** Increased interest from institutional investors and analysts can signal that a company is gaining credibility and visibility, making it a more attractive candidate for listing on major exchanges.
7. **Strong Corporate Leadership:** Having experienced and respected management can increase investor confidence and make a company more appealing to major exchanges.
8. **Positive Market Perception:** Favorable market sentiment and a strong reputation within the industry can contribute to a company's eligibility for listing on major exchanges.
9. **Industry and Sector Trends:** Being part of a growing or high-demand industry sector can make a company more appealing to major exchanges.
10. **Corporate Events:** Significant corporate events such as mergers, acquisitions, or successful product launches may attract attention and increase the likelihood of an uplift to a major exchange.
These indicators, among others, can suggest that a company is ready or considering an uplift to the NYSE or another major exchange. However, each company's situation is unique, and uplift decisions are typically made after careful consideration by company management and consultation with legal and financial advisors.
So counterintuitive more than twice average volume.
Stock barely nudges, seems like a short gave up and just covered to get his money out
Man what a piece of work Lisa is.
Roping her investors into paying for her mistakes and her story keeps changing on the fly to suit her and her only. Incredibly dubious intentions this gal, watch your back.
Dumb question perhaps but why agree to R/S
Sure it may come out over $5
,might not. So why take that chance, surely you don't owe management any favours. They screwed up, are screwing up, will screw up. Why split when you can simply say no. As I read earlier 74% of the float was Retail investors. You hold majority. First time I heard of any penny traders wanting an R/S...
2,500,000 shares traded, over twice normal volume.
Someone knows something...
If your allegations are indeed true then the SEC is not only complicit. In the eyes of the law, complicitness is without a doubt an act of criminality.
Algorithmic trades follow a predetermined instruction set. It doesn't necessarily need to make sense to anyone but the owner. eg. It could be company employees buying options and or selling options instead of any algorhithm. It could be an a super safe algorithm programmed and happy as a clam with modest gains.
I believe these unexplained fund managers are for now intellectual property the company can't disclose. Our CEO naturally knows his investors are exceedingly curious why they all show up on mass like that. Yet he decides to lay low on them, huh? I don't for a second believe it's spite or even nefarious. I opine it's more prudent management keeping sensitive information away from competitors until the deal closes, or some other indicator that all is good to go.
Clearly! Something pending is very significant indeed. So important he cannot talk about it yet. That is just good business acumen then, now isn't it? 🤔
Good on you playing company at there own game.
It's an unenviable situation when you know and fully anticipate the CEO to make horrifying gaffs at every turn. I was all set to do the same but made a fateful error sharing info I had doubled down that evening here.
My hunch is that was simply to much to resist and she launched her well prepared R/S notice early the next morning. I knew she was no stranger to these ruthless actions but after only 3 days in the stock there was another threat of an R/S, the rumors could not have been made clearer.
She has clearly signalled her intent here and there's 3 cardinal rules in investing:
1) preservation of capital
2) preservation of capital
3) preservation of capital
It doesn't make sense or logic that she would Savage her investors repeatedly for 4 years in a row when there are other sources of funding. I don't know that it's illegal but I sure is shooting noise incredibly dishonorable. I'm giving her a white her birth this time she can't be trusted that's all, she's proven it. When I saw Jaguar health had 74% retail investors on board, my jaw dropped. I didn't listen to my gut and for sure I should have. A lack of institutional investors substituted by one questionable Institutional Investor is a huge red flag. I'm out till it goes either way, I have ZERO trust and ZERO faith this CEO knows what she is doing.
Sidelines are the only* way I can risk capital with this company manageably. I'm watching closely, watching my capital much closer. Ghastly horrid management, awesome product. Good luck to you!
I clearly recall a lot* of complaints & protests. Particularly irritating were a LOT of 100 share buys and the criticism they must be computerized algorithimic trades...
SEC Regulation SHO (Reg SHO) is a set of rules implemented by the U.S. Securities and Exchange Commission (SEC) to regulate short selling and prevent abusive practices in the stock market. Hedge funds , like other market participants, are subject to Regulation SHO when engaging in short selling activities.
Hedge funds may become culpable under Regulation SHO if they engage in illegal or manipulative short selling practices, such as naked short selling (selling shares short without borrowing them or ensuring they can be borrowed) or engaging in fraudulent activities to manipulate stock prices.
Regulation SHO applies to all market participants involved in short selling, including hedge funds, broker-dealers, and institutional investors. Violations of Regulation SHO can result in enforcement actions by the SEC, including fines, penalties, and restrictions on trading activities.
It's essential for hedge funds and other market participants to adhere to Regulation SHO guidelines to maintain market integrity and protect investors from abusive practices.
Is it just my imagination playing tricks on me.
Or has RegulationSHO got a ways to go...yet. 🤔
Fatalistic emotions, extremely rare trading logic.
Recognising those emotions as the fear of the unknown is a good point to ponder. Unless you're ringing some invisible fire alarm. Then by all means Indulge me.
Market sentiment so comatose I'm talking to myself.
Can't come soon enough
One of the most poorly supported stocks I've seen in a long time. The CEO needs to make himself more available on X or FB or something. Mum is the word isn't helping. The wolves have been picking this thing off one appendage at a time, for weeks if not months, today no exception. Obvious they're after ever cheaper cheapies, possibly a competitor, not clear. Thanks, were you in conversation with him (CEO)?
As vile a fraud as that sure seems
Sonendo is claiming that will be past history. Cleanflow® Procedure Tool works from OUTSIDE the teeth. Pretty cool right, but that's all they're giving out so far. More to come obviously but with about 10 different procedures it can improve very significantly on... We are clearly talking serious disrupter technology industry wide.
Scroll way down https://sonendo.com/gentlewave-system#:~:text=The%20CleanFlow%E2%84%A2%20procedure%20instrument,from%20outside%20of%20the%20tooth.
Crike Mate of course that's it's forte, seriously?
I hunch my first taste of PTSD was the smell of fresh drilled tooth enamel. Young gun dentist, a little to motivated if you know what I mean. Thought he was attempting brain surgery TBH.
Can't recall exact number but 95% of patients reported no pain at all. I hunch a big reason for that is, it's AI driven bubble stream prevents a lot of drilling in the first place. There's that Preventitive dentistry again, can't beat it!
Last year's news for this year's pump?
That's definitely not you. Lisa must be getting to you. She made such an error in that British interview the editor had to correct her in print. Not quite sure what this woman is on but is that what's got you all out of sorts? Easy now, been there, feel your pain. They haven't figured out a pill for it yet, so be careful.
Jumping to conclusion sure causes confusion.
The PR is from March 13th 2023. Have another coffee...
He's in no panic, told me straight out.
If NYSE doesn't pan out. Nasdaq he goes a knocking. If that doesn't work. Then I swear as sure as I'm sitting here, he's quite happy where he is. That was a surprise, a little counterintuitive truth be told.
Uplisting is just not the main event for Bjarne. He has uplisting in the back of his mind I could tell. But first and foremost (by a wide margin) building the company is in his crosshairs. This is one confident, determined and motivated CEO.
When would you best prefer SONX uplist 🤔
When do you think the timing might be optimal for Sonendo? Don't forget he needs very significant news to pull off a green light from NYSE
For a moment think back to Valsoft "partnership"
This business model restructuring for certain required some Sonendo employees to find employment elsewhere (perhaps even Valsoft) . Also some would be more inclined to stay with the company in a different category because loyalty runs deep to Sonendo. I believe Valsoft partnership is at least in part what precipitated employee shares to be more incentivized. Therefore more made available even if that Sonendo employee moved to Quebec for a while.
Sonendo had to put more employees into building sales through more intense lab research, facilitating faster time to market for Clean Flow Procedure Tool. Valsoft acquired TDO Software to build for a different application so they can go into vertical markets.
Vertical market customization is exactly in keeping with what I would expect, if Sonendo was to capitalize on the Canadian free dental program. But Valsoft is not restricted to just the Canadian market alone! No folks they're almost certainly also working on Sonendo software for the US medical system.
Whatever you do in your DD DO NOT UNDERESTIMATE the significance of this much blurred out Valsoft Corporation "Partnership" . That would be a crucial oversight on the future of this company and your profit margin.
There definitely appears to be a liquidity problem.
This isn't only effecting SONX trust me. Bjarne could be timing his uplisting for maximum liquidity as well. April and May are good target dates in such an instance. That gives him enough time to get a better bead on Clean Flow Procedure Tool progress. Clean flow is a huge Revenue stream once it comes fully online, be very certain of that.
Once SONX up lists the Media will be all over Bjarne like a dirty shirt. It's then (after uplisting) that he's far more prone to describe the incredible potential IMHO.
Bjarne might need more institutional support 🤔
That could explain why these fund managers could easily be accumulating. I'm convinced some entity is accumulating and possibly MM's are helping (that's pure speculation)
A stock price might channel, or trade within a relatively narrow range, before uplifting to a higher exchange due to several reasons:
1. Accumulation: Institutional investors or insiders may be accumulating shares of the company, leading to a period of consolidation and relatively stable prices before a significant move.
2. Market sentiment: Investors might be awaiting news or developments that could affect the company's valuation before committing to buying or selling shares, causing the stock price to channel.
3. Technical factors: Traders may be observing key technical levels, such as support and resistance levels, causing the stock price to trade within a defined range until a catalyst prompts a breakout.
4. Lack of liquidity: If there is limited liquidity in the stock, it may lead to periods of consolidation as buyers and sellers struggle to find a price equilibrium.
5. Regulatory requirements: The company may need to meet certain listing requirements or regulatory standards before uplifting to a higher exchange, leading to a period of preparation and consolidation in the stock price.
Overall, the stock price channeling before uplifting to a higher exchange could be influenced by a combination of fundamental, technical, and market-specific factors.
Each of these procedures requires optimum Hygiene.
Endodontics and general dentistry involve different procedures focused on different aspects of dental care:
Endodontic procedures (root canal treatment):
1. Root canal therapy: This involves removing infected or damaged pulp from inside the tooth, cleaning and disinfecting the root canals, and sealing them to prevent further infection.
2. Apicoectomy: In cases where a root canal treatment is unsuccessful or cannot be performed conventionally, an apicoectomy involves removing the tip of the tooth's root and sealing the end of the root canal.
3. Pulpotomy: Partial removal of the pulp tissue is performed in cases where the infection is limited to the crown of the tooth, typically in pediatric dentistry.
General dentistry procedures:
1. Dental exams and cleanings: Routine check-ups and professional cleanings to maintain oral health and detect any dental issues early.
2. Fillings: Repairing cavities by removing decayed tooth material and filling the space with materials like amalgam or composite resin.
3. Extractions: Removal of severely damaged, decayed, or impacted teeth.
4. Crowns and bridges: Restoring damaged or missing teeth with prosthetic devices that cover or replace the tooth.
5. Dental implants: Surgical placement of artificial tooth roots to support replacement teeth.
6. Dentures: Removable prosthetic devices used to replace missing teeth and surrounding tissues.
While endodontics focuses specifically on treating issues related to the pulp and root of the tooth, general dentistry encompasses a broader range of preventive, restorative, and cosmetic dental procedures.
I want a 10 digit S/P IHUB, 6 digit so passé
The Clean Flow Procedure Tool numbers are going to shock a few people that's a given...
I've had time to reflect on Year Ends Train Wreck
A few things that precipitated A SONX sell off Tuesday IMO. One was extremely ominous. Many here were complaining that the stock wasn't rising in anticipation of the filing. I saw it as butterflies, but when the share price stayed glued to 17 cents and didn't even rise towards Monday's close? I got the jitters, no doubt others did too. Perhaps it was a tip off for some I'm not sure but storm clouds clearly gathered from my vantage point.
A lot of effort was made here to alert newbies this was only* a 10-Q don't expect other news and definitely don't think any uplisting was imminent. Fact is it only takes one misinformed guy figuring this was an uplisting that sells off hard to create panic selling and sure enough S/P nose dived precipitously.
The Valentine's Day excitement of 4 fund managers drove up high expectations big news was imminent. Why not anyone would think that! I think in retrospect these Fund Managers arrived because of Clean Flow Procedure Tool and the growth it would bring. I think they are right too anticipate that too.
I'll be doing more research but claims of shorting naked shorts or aka Air Shares could be accurate. The share price did not rise to the year end PR. I'm sure that's a clear indicator something was clearly off, not right either. The employee incentivization shares on top of the fund managers preferred shares could well have been the straw that broke the camel's back. That was a lot to swallow given the fact there was no transparent news per se. One had to read between the lines for any upcoming events.
Feel free to add anything you think I missed but as many here said before the 4th quarter filing. SONX needs some good news or we are going to die on the vine. That observation is still true going into this morning's trading. SOMETHING to cheer about would sure help the stock for sure. Congrats to those that had more powder to scoop up the cheapies, what a score!